Thiazovivin (SKU A5506): Practical Guidance for ROCK Inhibition in Stem Cell Research

What This Product Solves

Thiazovivin (CAS No. 1226056-71-8) is a selective small molecule ROCK inhibitor designed for laboratory research applications, particularly in the context of stem cell workflows. Its primary uses include improving the efficiency of fibroblast reprogramming to induced pluripotent stem cells (iPSCs) and promoting survival of human embryonic stem cells (hESCs) during processes such as trypsinization. These applications address two persistent technical bottlenecks: low reprogramming yield and poor cell viability post-dissociation. By incorporating Thiazovivin into reprogramming or passaging protocols, researchers can mitigate cell death and support more reproducible, high-yield outcomes (product_spec).

Thiazovivin is not suitable for diagnostic or clinical use and should only be applied in research settings with established QC and safety protocols.

Protocol Parameters

• assay: Stock solution preparation | value_with_unit: ≥15.55 mg/mL in DMSO | applicability: Ensures complete solubility for consistent dosing | rationale: The compound is confirmed soluble at this concentration, supporting preparation of high-concentration stocks for downstream dilution | source_type: product_spec
• assay: Storage (powder) | value_with_unit: -20°C | applicability: Maintains compound integrity and prevents degradation during long-term storage | rationale: Thiazovivin is a solid and should be kept at -20°C for best stability | source_type: product_spec
• assay: Working solution use | value_with_unit: Use promptly after dilution; avoid long-term storage | applicability: Ensures biological activity is retained for experimental reliability | rationale: Solutions degrade over time; prepare fresh aliquots before each assay to maximize effect | source_type: product_spec
• assay: Combination use | value_with_unit: Use with SB 431542 and PD 0325901 | applicability: Enhances fibroblast reprogramming efficiency to generate iPSCs | rationale: Synergistic effects with other inhibitors are workflow recommendations based on product context | source_type: workflow_recommendation

Workflow Setup and QC Checklist

• Confirm the identity and purity of Thiazovivin (98.00%) prior to use (product_spec).
• Prepare stock solutions in anhydrous DMSO at concentrations up to 15.55 mg/mL, filter-sterilizing if required by downstream applications.
• Store solid compound at -20°C. Avoid repeated freeze-thaw cycles.
• Upon dilution to working concentrations, use solutions promptly. Do not store diluted Thiazovivin long-term.
• Shipments arrive with cold packs (blue ice); verify temperature maintenance upon receipt.
• For iPSC generation, consider combining Thiazovivin with SB 431542 and PD 0325901 as per established workflow recommendations (source: workflow_recommendation).
• Record batch and lot numbers for all reagents used, including Thiazovivin, to ensure traceability.
• Include appropriate controls (vehicle, untreated, and positive controls) in all experiments.

For detailed, scenario-driven workflow optimization, see Optimizing Stem Cell Assays with Thiazovivin, which expands on assay reproducibility and protocol troubleshooting.

Common Failure Modes and Fixes

• Incomplete solubilization in DMSO: Ensure the use of anhydrous, room temperature DMSO and vortex or gently heat if needed; do not exceed the recommended solubility threshold.
• Loss of activity in stored solutions: Prepare fresh working solutions right before each experiment to avoid potency loss; dispose of any unused, diluted solutions after use.
• Poor cell survival after passaging: Verify the freshness and proper concentration of Thiazovivin; check for synergistic support from companion inhibitors in iPSC protocols.
• Unexpected cytotoxicity: Confirm concentration calculations and solvent compatibility; include vehicle controls to rule out DMSO effects.
• Contamination: Use sterile technique throughout preparation, especially when working with sensitive stem cell lines.

Additional troubleshooting strategies are discussed in Practical Solutions for Cell Survival: Thiazovivin, focusing on common workflow pitfalls and laboratory QC.

Scope and Limitations

• Thiazovivin is validated for use as a ROCK inhibitor in workflows involving induced pluripotent stem cell generation and human embryonic stem cell survival (product_spec).
• The compound’s primary effectiveness is established when used alongside other pathway inhibitors; its standalone effect may be limited in certain reprogramming applications.
• Not intended for in vivo, diagnostic, or therapeutic use. All data and recommendations are provided for laboratory research only.
• Quantitative performance metrics (e.g., percent survival increase or reprogramming yield) are not specified in the product dossier and should be empirically determined in each lab’s system.
• Batch-to-batch QC and workflow validation remain essential due to potential variance in cell line responses.

Conclusion

Thiazovivin (A5506) provides a targeted approach for overcoming technical barriers in stem cell research, specifically by enhancing fibroblast reprogramming and supporting hESC survival through ROCK signaling pathway inhibition. Its utility is well defined for research use where controlled cell fate engineering is required. For full product details, QC practices, and ordering information, refer to the APExBIO Thiazovivin page.